Holen Sie sich die Stockscreener-App
26.62
1.10%
0.29
Schlusskurs vom Vortag:
$26.33
Offen:
$26.12
24-Stunden-Volumen:
589.66K
Relative Volume:
0.54
Marktkapitalisierung:
$2.01B
Einnahmen:
$122.87M
Nettoeinkommen (Verlust:
$-73.68M
KGV:
-27.15
EPS:
-0.9803
Netto-Cashflow:
$-39.27M
1W Leistung:
-0.93%
1M Leistung:
+6.06%
6M Leistung:
+106.52%
1J Leistung:
+80.11%
1-Tages-Spanne:
$25.68
$26.84
1-Wochen-Bereich:
$25.68
$26.91
52-Wochen-Spanne:
$9.03
$28.49
Zymeworks Inc. Stock (ZYME) Company Profile
Firmenname
Zymeworks Inc.
Sektor
Branche
Telefon
604-678-1388
Adresse
1385 West 8th Avenue, Suite 540, Vancouver, BC
Vergleichen Sie ZYME mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ZYME
Zymeworks Inc.
|
26.62 | 1.99B | 122.87M | -73.68M | -39.27M | -0.9803 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Zymeworks Inc. Stock (ZYME) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-12 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2025-12-03 | Eingeleitet | Citizens JMP | Mkt Outperform |
| 2025-10-24 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2025-10-14 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-10-10 | Eingeleitet | B. Riley Securities | Buy |
| 2025-05-20 | Eingeleitet | TD Cowen | Buy |
| 2024-12-16 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-11-07 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-11-01 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-03-21 | Fortgesetzt | Wells Fargo | Overweight |
| 2023-01-04 | Bestätigt | H.C. Wainwright | Neutral |
| 2022-12-20 | Hochstufung | Jefferies | Hold → Buy |
| 2022-11-01 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2022-10-21 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-10-04 | Fortgesetzt | Wells Fargo | Overweight |
| 2022-05-05 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-03-15 | Eingeleitet | Evercore ISI | Outperform |
| 2021-12-10 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-11-17 | Fortgesetzt | Guggenheim | Neutral |
| 2021-10-07 | Eingeleitet | Jefferies | Hold |
| 2021-03-31 | Eingeleitet | Credit Suisse | Outperform |
| 2021-02-25 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-02-08 | Fortgesetzt | H.C. Wainwright | Buy |
| 2021-01-25 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-09-29 | Fortgesetzt | JP Morgan | Neutral |
| 2020-08-06 | Eingeleitet | SVB Leerink | Outperform |
| 2020-01-10 | Eingeleitet | Wolfe Research | Outperform |
| 2019-12-09 | Eingeleitet | JP Morgan | Neutral |
| 2019-11-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-11-20 | Eingeleitet | Guggenheim | Buy |
| 2019-09-30 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2019-08-30 | Eingeleitet | Stifel | Buy |
| 2019-07-18 | Eingeleitet | Deutsche Bank | Buy |
| 2018-05-11 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2018-03-19 | Eingeleitet | Raymond James | Outperform |
Alle ansehen
Zymeworks Inc. Aktie (ZYME) Neueste Nachrichten
Zymeworks Inc: Can ZYME’s Quiet Rally Turn Into a Breakout Story? - AD HOC NEWS
Zymeworks shareholders elect directors and approve compensation at annual meeting - Investing.com
Zymeworks Shareholders Back Directors, Executive Pay and Auditor - TipRanks
Short Interest in Zymeworks Inc. (NASDAQ:ZYME) Drops By 29.8% - MarketBeat
Zymeworks Announces Participation in Upcoming Investor Conferences - Macau Business
Kenneth Galbraith Sells 47,528 Shares of Zymeworks (NYSE:ZYME) Stock - MarketBeat
Zymeworks Insider Sold Shares Worth $1,284,311, According to a Recent SEC Filing - marketscreener.com
Is Zymeworks Inc. stock vulnerable to regulatory risksBull Run & Daily Chart Pattern Signal Reports - Улправда
How rising interest rates impact Zymeworks Inc. stockIndex Update & AI Based Buy/Sell Signal Reports - ulpravda.ru
Zymeworks Inc. $ZYME Shares Purchased by Assenagon Asset Management S.A. - MarketBeat
Aug Fed Impact: How rising interest rates impact Zymeworks Inc. stockTrade Entry Report & Expert-Curated Trade Recommendations - Улправда
Will Zymeworks Inc. stock benefit from upcoming earnings reportsProduct Launch & Technical Confirmation Alerts - Улправда
Why retail investors pile into Zymeworks Inc. stock2025 Winners & Losers & Low Drawdown Investment Strategies - DonanımHaber
Is Zymeworks Inc. (NASDAQ:ZYME) Trading At A 50% Discount? - Yahoo Finance
Zymeworks Inc. $ZYME Shares Acquired by Squarepoint Ops LLC - MarketBeat
Zymeworks Inc. (NASDAQ:ZYME) Receives Average Rating of "Buy" from Analysts - MarketBeat
How institutional buying supports Zymeworks Inc. stockPortfolio Gains Report & Community Verified Swing Trade Signals - ulpravda.ru
Free cash flow per share of Zymeworks Inc. – TRADEGATE:ZA8 - TradingView — Track All Markets
Buy Signal: How rising interest rates impact Zymeworks Inc. stockMarket Activity Recap & Trade Opportunity Analysis - Улправда
Will Zymeworks Inc. (ZA8) stock return to pre crash levelsJuly 2025 PreEarnings & Smart Money Movement Alerts - Улправда
Truist Initiates Zymeworks at Buy With $40 Price Target - marketscreener.com
How FDA Approval of Zanidatamab in HER2 Biliary Cancer Will Impact Zymeworks (ZYME) Investors - Sahm
Zymeworks (NASDAQ:ZYME) Stock Rating Upgraded by Wells Fargo & Company - MarketBeat
Zymeworks (NYSE:ZYME) Shares Gap UpWhat's Next? - MarketBeat
Zymeworks (NASDAQ:ZYME) Shares Gap UpHere's What Happened - MarketBeat
EcoR1 Capital LLC Increases Stake in Zymeworks Inc. $ZYME - MarketBeat
Zymeworks Inc. (NYSE:ZYME) Receives Average Rating of "Buy" from Brokerages - MarketBeat
Wells Fargo Upgrades Zymeworks (ZYME) - Nasdaq
Zymeworks (ZYME) Receives Rating Upgrade and Increased Price Tar - GuruFocus
Redmile Group LLC Sells 638,318 Shares of Zymeworks Inc. $ZYME - MarketBeat
Could Zymeworks' blockbuster drug success revive Vancouver biotech scene? - Business in Vancouver
Norges Bank Buys New Shares in Zymeworks Inc. $ZYME - MarketBeat
Zymeworks (ZYME) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Zymeworks to Engage in Key Investor Conferences - MSN
Zymeworks (ZYME) Is Up 5.2% After First FDA Approval For Zanidatamab And Royalty ShiftHas The Bull Case Changed? - Sahm
Zymeworks (ZYME): Reassessing Valuation After FDA Zanidatamab Approval and a Sharp Share Price Rally - Sahm
Zymeworks Inc Stock Analysis and ForecastPrice Momentum Alerts & Low Entry Investment Plans - earlytimes.in
Zymeworks (ZYME) Price Target Increased by 42.94% to 35.19 - Nasdaq
How higher bond yields impact Zymeworks Inc. (ZA8) stockPortfolio Update Report & Weekly Setup with ROI Potential - Newser
Is Zymeworks Inc. (ZA8) stock cheap vs fundamentalsPortfolio Value Report & Long Hold Capital Preservation Tips - Newser
What technical patterns form on Zymeworks Inc. (ZA8) stock chartsWeekly Gains Summary & Short-Term Swing Trade Alerts - Newser
Is Zymeworks Inc. (ZA8) stock considered safe havenInsider Selling & AI Powered Market Trend Analysis - Newser
Will Zymeworks Inc. (ZA8) stock maintain strong growth2025 Earnings Impact & Safe Capital Allocation Plans - Newser
Zymeworks to Showcase Innovative Biotherapeutics at Upcoming Conferences - MSN
Citizens Initiates Coverage of Zymeworks (ZYME) with Market Outperform Recommendation - Nasdaq
How Zymeworks Inc. (ZA8) stock performs in volatility spikesJuly 2025 Gainers & Verified Technical Signals - Newser
Zymeworks Announces Participation in Upcoming Conferences - The Manila Times
Zymeworks Inc. Announces Participation in ASCO GI and J.P. Morgan Healthcare Conference, Highlighting Advances in HER2-Driven Gastrointestinal Cancers and Novel Drug Developments - Quiver Quantitative
Is Zymeworks Inc. (ZA8) stock supported by strong fundamentalsAnalyst Upgrade & Accurate Intraday Trade Tips - Newser
Finanzdaten der Zymeworks Inc.-Aktie (ZYME)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.57%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):